Evidence map›Paper›PMID 25984332›Full record

ReviewRegenerative medicine research2014

Human induced pluripotent stem cell for modeling cardiovascular diseases.

Ping Liang, Jie Du

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Regenerative medicine research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Ping LiangDepartment of Medicine, Division of Cardiology, Stanford University, Stanford, CA USA ; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA USA ; Cardiovascular Institute, Stanford University, Stanford, CA USA ; Lorry I. Lokey Stem Cell Research Building, Rm G1105, 265 Campus Drive, Stanford, CA 94305 USA.
Jie DuBeijing Anzhen Hospital, Capital Medical University, Beijing, China ; The key laboratory of Remodeling-related Cardiovascular Disease, Ministry of Education, Capital Medical University, Beijing, China ; Beijing Institute of Heart Lung & Blood Vessel Disease, Beijing, China.
Capital Medical University · CNStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The invention of the induced pluripotent stem cell (iPSC) technology allows patient-specific, mature somatic cells to be converted into an unlimited supply of pluripotent stem cells (PSCs). These iPSCs can then in turn be differentiated into any cell type including neurons, cardiac cells, pancreatic cells, liver cells, blood cells or enterocytes. Although cardiovascular disease (CVD) is a leading cause of death in the world, the limited cell derivation and cell number in cardiac tissue makes it difficult to study the CVDs using the existing cardiac cell model. By differentiating the patient-specific iPSCs into cardiomyocytes, scientists can generate iPSC-based 'disease in a dish' models and use them to better understand disease mechanism. Here we review the current progress in using iPSC-derived cardiomyocytes to model human CVDs.

Indexed as

Cardiovascular diseaseDisease modelingInduced pluripotent stem cellsStem cells

Identifiers

PMID25984332
PMCPMC4389800
OpenAlexW2100217179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.